The Spark Stack (Hers)

PT-141 targets desire centrally; oxytocin supports connection; the estradiol/DHEA cream addresses local comfort and tissue health that can affect intimacy, especially around perimenopause. Together: desire, connection, and comfort.

PT-141 has the strongest standing — FDA-approved for hypoactive sexual desire disorder in premenopausal women based on randomized trials. Local estrogen therapy is well-established for genitourinary comfort. Oxytocin's intimacy use is more preliminary. Expectations track those evidence levels.

PT-141 commonly causes nausea and can transiently raise blood pressure (screened in cardiovascular risk). Hormone components carry real considerations — local estrogen is generally lower-risk than systemic, but personal history (hormone-sensitive cancers, clotting risk) guides use; DHEA can cause androgenic effects like acne. This is why the cream is provider-tailored.